Ameloblastoma Cell Line Resource

Ameloblastoma (AB) is an odontogenic tumor that is locally destructive to the jaw bone. Treatment entails surgical resection, but AB often recurs locally. Recent driver mutations have been identified in the MAPK and Hedgehog pathways. However, translation to molecularly-targeted therapies has been hampered by the lack of AB cell line models. The goal of our study has been to create a new AB cell line resource that reflects the spectrum of AB driver mutations. We created 6 new AB cell lines, and by targeted exome sequencing, defined their driver mutations. We showed the utility of these cell lines in preclinical studies of oncogene dependence and drug sensitivity (which includes whole transcriptome assays).

• Study Design:
  • Case Set
• Study Type:
  • Exome Sequencing
  • Transcriptome Sequencing
  • Tumor
• Total number of consented subjects: 6
• Subject Sample Telemetry Report (SSTR)

• BioProject
• PubMed
• Sequence Read Archive
• PMC

All tissue specimens were acquired with IRB approval and patient informed consent, from surgical excisions done at Stanford Hospital for the treatment of primary or recurrent ameloblastoma. Altogether, the study included ameloblastoma tissue specimens from 6 subjects, from which cell lines were derived and characterized by targeted exome sequencing and whole-transcriptome sequencing.

• Primary Phenotype: Ameloblastoma
• Odontogenic Tumors

• Principal Investigator
  • Jonathan Pollack, MD, PhD. Stanford University, Stanford, CA, USA.
• Co-Investigator
  • Robert West, MD, PhD. Stanford University, Stanford, CA, USA.
• Funding Source
  • R01 DE026502. National Institutes of Health, Bethesda, MD, USA.